FORWARD FEATURES CALENDAR

Deals & Transactions

Partners Group in exclusive discussions to exit investment in Cerba HealthCare

Cerba HealthCare (Cerba HealthCare), together with Partners Group, a global private markets firm, and the Public Sector Pension Investment Board (PSP Investments), one of Canada’s largest pension investment managers, has entered into exclusive discussions with the EQT IX fund (EQT Private Equity) to enable the Company to continue its long-term

Mid Europa invests in e-commerce platform Piqu

Mid Europa Partners (Mid Europa) is to acquire UAB Pigu (Piqu), an e-ccomerce platform focussed on the Baltic countries.  Additionally, Mid Europa has agreed with MCI.Euroventures and the founding shareholders of Pigu and Hobby Hall Group OÜ (HHG) to combine Pigu and HHG to create one of the leading e-commerce

Citizens advises Telestream on Masstech acquisition

Citizens M&A Advisory served as the exclusive financial advisor to Telestream in its acquisition of Masstech.  Telestream, a portfolio company of Genstar Capital, is a vertical market software business focused on the video space and is a global leader in media workflow orchestration, media streaming and delivery technologies. Masstech, based

Blue Point Capital Partners acquires Cascadia Custom Molding

Blue Point Capital Partners (Blue Point) and its Blue Point IV portfolio company, VRC Engineered Solutions (VRC), has acquired Cascadia Custom Molding (Cascadia). The acquisition will expand VRC’s product offerings and geographic footprint while enhancing manufacturing capabilities and diversifying end markets served.  For over 40 years, Cascadia has provided high-quality

LIVEKINDLY Collective raises USD335m

LIVEKINDLY Collective, a collection of heritage and start-up brands on track to become one of the world’s largest plant-based food companies, has completed a capital raise led by The Rise Fund, a global impact investing platform managed by TPG.  This round was joined by Rabo Corporate Investments, the investment arm

Arix leads USD152m Series B financing for Pyxis Oncology

Arix Bioscience (Arix), a global venture capital company focused on investing in and building breakthrough biotech companies, has invested in Pyxis Oncology (Pyxis). As part of the deal, Arix Managing Director Christian Schetter will join Pyxis’ Board of Directors. Pyxis is building a differentiated portfolio of biologics, including antibody-drug conjugates

Events

12 November, 2026 – 5:00 pm

Directory Listings